Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
02 Sep 2020 07:00 AM
RNS
Placing to raise £6.5 million
01 Sep 2020 07:00 AM
RNS
Holding(s) in Company
27 Jul 2020 07:00 AM
RNS
FDA submission for Special Protocol Assessment
18 Jun 2020 11:31 AM
RNS
2020 AGM - ALL RESOLUTIONS PASSED
16 Jun 2020 07:00 AM
RNS
Total Share Capital Notification
11 Jun 2020 12:00 PM
RNS
TR-1 Notification of major holdings
11 Jun 2020 07:00 AM
RNS
STRAT. INVTS FROM 2 SPECIALIST US H'CARE INVESTORS
05 Jun 2020 07:00 AM
RNS
Change of Registered Office Address
02 Jun 2020 07:00 AM
RNS
Notification of Change of AGM Venue
21 May 2020 07:00 AM
RNS
Notice of AGM and posting of Report & Accounts
18 May 2020 01:45 PM
RNS
TR-1: Notification of major holdings
14 May 2020 07:00 AM
RNS
Efforts in fight vs Covid-19 with Lupuzor; Ureka
30 Apr 2020 09:57 AM
RNS
Audited Report & Accounts published on website
30 Apr 2020 07:00 AM
RNS
FINAL RESULTS FOR THE 12M ENDED 31/12/19
06 Apr 2020 07:00 AM
RNS
IMM live on Investor Meet Company platform 7 April
03 Apr 2020 03:55 PM
RNS
Holding(s) in Company
02 Apr 2020 08:26 AM
RNS
Holding(s) in Company
31 Mar 2020 04:41 PM
RNS
Second Price Monitoring Extn
31 Mar 2020 04:37 PM
RNS
Price Monitoring Extension
31 Mar 2020 12:07 PM
RNS
Second Price Monitoring Extn
31 Mar 2020 12:02 PM
RNS
Price Monitoring Extension
30 Mar 2020 08:02 AM
RNS
£1.5m Subscrip'n to fund R&D pipeline- replacement
30 Mar 2020 07:00 AM
RNS
£1.5m Subscription to fund R&D pipeline expansion
20 Mar 2020 04:45 PM
RNS
Second Price Monitoring Extn
20 Mar 2020 04:40 PM
RNS
Price Monitoring Extension
18 Mar 2020 04:42 PM
RNS
Second Price Monitoring Extn
18 Mar 2020 04:37 PM
RNS
Price Monitoring Extension
16 Mar 2020 04:43 PM
RNS
Second Price Monitoring Extn
16 Mar 2020 04:39 PM
RNS
Price Monitoring Extension
04 Mar 2020 04:35 PM
RNS
Price Monitoring Extension
28 Feb 2020 07:03 AM
RNS
Incanthera plc - Admission to trading on NEX
21 Feb 2020 04:35 PM
RNS
Price Monitoring Extension
17 Feb 2020 08:00 AM
RNS
Incanthera announces Rule 23 Notice re NEX listing
12 Feb 2020 04:41 PM
RNS
Second Price Monitoring Extn
12 Feb 2020 04:35 PM
RNS
Price Monitoring Extension
06 Feb 2020 07:00 AM
RNS
Update on the Avion Agreement
05 Feb 2020 04:40 PM
RNS
Second Price Monitoring Extn
05 Feb 2020 04:35 PM
RNS
Price Monitoring Extension
07 Jan 2020 04:40 PM
RNS
Second Price Monitoring Extn
07 Jan 2020 04:35 PM
RNS
Price Monitoring Extension
19 Dec 2019 04:35 PM
RNS
Price Monitoring Extension
19 Dec 2019 07:00 AM
RNS
Admission today to trading on Euronext Growth
17 Dec 2019 07:00 AM
RNS
Publication of Information Note (Euronext Growth)
13 Dec 2019 07:00 AM
RNS
Dual Listing on Euronext Growth Brussels
11 Dec 2019 12:49 PM
RNS
Share Price Volatility
03 Dec 2019 07:00 AM
RNS
IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASET 2020
02 Dec 2019 07:00 AM
RNS
TR-1: notification of major holdings
28 Nov 2019 07:00 AM
RNS
Licence Agreement for Lupuzor with Avion in US
25 Nov 2019 04:41 PM
RNS
Second Price Monitoring Extn
25 Nov 2019 04:35 PM
RNS
Price Monitoring Extension

ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France. 

ImmuPharma listed on AIM under the ticker IMM. 

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

IMM share price listed in London at 1,190p in 2000. 

UK 100

Latest directors dealings